Cyclo Therapeutics Stock Current Asset
| CYTH Stock | USD 0.64 0.08 11.11% |
Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.
As of now, Cyclo Therapeutics' Other Current Assets are increasing as compared to previous years. The Cyclo Therapeutics' current Total Current Assets is estimated to increase to about 12.9 M, while Non Current Assets Total are projected to decrease to under 694.6 K. Cyclo | Current Asset |
Cyclo Therapeutics Company Current Asset Analysis
Cyclo Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Cyclo Current Asset Historical Pattern
Today, most investors in Cyclo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cyclo Therapeutics current asset as a starting point in their analysis.
Cyclo Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Cyclo Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Cyclo Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Cyclo Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in current asset category among its peers.
Cyclo Fundamentals
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 | ||||
| Operating Margin | (45.78) % | ||||
| Current Valuation | 29.76 M | ||||
| Shares Outstanding | 28.77 M | ||||
| Shares Owned By Insiders | 40.07 % | ||||
| Shares Owned By Institutions | 13.17 % | ||||
| Number Of Shares Shorted | 131.61 K | ||||
| Price To Book | 59.10 X | ||||
| Price To Sales | 18.29 X | ||||
| Revenue | 1.08 M | ||||
| Gross Profit | 1.23 M | ||||
| EBITDA | (20.03 M) | ||||
| Net Income | (20.06 M) | ||||
| Cash And Equivalents | 4.29 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 1.03 M | ||||
| Current Ratio | 2.93 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (16.19 M) | ||||
| Short Ratio | 3.82 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Target Price | 0.95 | ||||
| Beta | -0.38 | ||||
| Market Capitalization | 20.71 M | ||||
| Total Asset | 13.25 M | ||||
| Retained Earnings | (83.86 M) | ||||
| Working Capital | 3.85 M | ||||
| Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Cyclo Therapeutics Piotroski F Score and Cyclo Therapeutics Altman Z Score analysis. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.